Results 141 to 150 of about 75,915 (258)
Background: Approximately 75% of drug metabolism in clinical settings is attributed to cytochrome P450 enzymes. This study aimed to assess the effects of the CYP3A4*1B and CYP3A5*3 genetic variations on the clinical results of ...
Heba M. Elmaraghy +7 more
doaj +1 more source
Microporous array organ chips were integrated with commercially available well plates to develop organoid chip platforms, which enable modelling of hepatic physiology and non‐alcoholic fatty liver disease (NAFLD) pathogenesis, as well as evaluation of semaglutide therapeutics. ABSTRACT Progressive non‐alcoholic fatty liver disease (NAFLD) may culminate
Xiao‐yan You +3 more
wiley +1 more source
Долгое время клинические исследования лекарственных средств I и II фазы у женщин не проводились, что было связано с опасениями негативного воздействия на возможную беременность и плод.
doaj
Učestalost polimorfizama CYP3A4*1B, CYP3A4*22 i CYP3A5*3 u hrvatskoj populaciji
Enzimi pod-porodice citokroma P450 3A (CYP3A) sudjeluju u metabolizmu oko 50% lijekova u kliničkoj primjeni. Najvažniji su enzimi CYP3A4 i CYP3A5, za koje je karakteristična interindividualna varijabilnost. Genetičke varijante mogu objasniti dio varijabilnosti aktivnosti CYP3A.
openaire +1 more source
Integrating gepants into clinical practice for the acute treatment of migraine
Abstract Objective To assess the role of small‐molecule calcitonin gene–related peptide receptor antagonists (gepants) in the acute treatment of migraine, particularly in relation to triptan treatments. Background Triptans have established efficacy and are widely prescribed for the acute treatment of migraine.
Richard B. Lipton +4 more
wiley +1 more source
Efficacy and Safety of Dronedar one in Overweight and Obesity: Post Hoc Analysis of the ATHENA Trial
ABSTRACT Introduction Obesity represents a prevalent condition with multiple comorbidities, including atrial fibrillation (AF). Dronedarone, an antiarrhythmic drug (AAD), has demonstrated efficacy in patients with paroxysmal/persistent AF and cardiovascular (CV) risk factors.
Mate Vamos +3 more
wiley +1 more source
Apremilast in Japanese patients with palmoplantar pustulosis: A randomized, Phase 3 trial
In this Phase 3 trial of Japanese patients with moderate to severe PPP (NCT05174065), significantly more patients achieved PPPASI‐50 at Week 16 with apremilast versus placebo. Patient‐reported outcomes, including pruritus and pain/discomfort, also showed significantly greater decreases at Week 16 with apremilast versus placebo.
Tadashi Terui +15 more
wiley +1 more source
For a century, Vitamin E has been studied for its health benefits. This review traces its journey from basic biological discovery, and the recent identification of its link to chlorophyll degradation, to the modern era of sustainable microbial manufacturing, highlighting the innovative technologies that define its future production.
Ruiqi Zhang +7 more
wiley +1 more source

